Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
Healthkick Podcast: Neuren is cashed up, confident and charging into a phase 3 trial
Experts
ScoPo’s powerplays: ‘It’s a new dawn… get in front of these extraordinary opportunities’
Health & Biotech
Antisense Therapeutics’ FDA ruling could be worth ‘hundreds of millions’
Health & Biotech
World-renown cancer institute to investigate Kazia Therapeutics drug
Health & Biotech
Incannex persists with CBD, hydroxychloroquine COVID drug
Health & Biotech
Health: Immutep has dosed the last patient in one of its cancer studies
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
The healthcare winners and losers after COVID-19, and what comes next
Experts
Scopo’s health powerplays: Clinical trials are back
Experts
Scopo’s health powerplays: Markets be crazy, buy the dip
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: Even bacteria fighter Next Science is feeling the coronavirus pinch
Health & Biotech
Health: Neuren’s mice are happily burying marbles after PMS neurotherapy
Health & Biotech
Health: Neuren gets extra FDA push for its treatment for rare Rett disease
Health & Biotech
Christmas may have come early for Biotron and its HIV cure
Health & Biotech
